UK markets close in 28 minutes

Chiasma, Inc. (CHMA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.7600-0.2400 (-6.00%)
As of 4:00PM EDT. Market open.

Chiasma, Inc.

Building C East
140 Kendrick Street
Needham, MA 02494
United States
617 928 5300
http://www.chiasma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees84

Key executives

NameTitlePayExercisedYear born
Mr. Raj KannanPres, CEO & Director827.55kN/A1964
Mr. Anand VaradanExec. VP & Chief Commercial Officer542.27kN/A1967
Mr. John Brendan DoyleSr. VP, CFO & TreasurerN/AN/A1977
Mr. Drew EnamaitVP of Fin. & Admin.N/AN/A1974
Ms. Dawn Schottlandt CFAVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Lee G. GiguereVP of Gen. Counsel & Sec.N/AN/A1980
Mr. Derek BrownVP of MarketingN/AN/AN/A
Mr. Joe LyonsExec. Director of HRN/AN/AN/A
Dr. William H. LudlamSr. VP of Clinical Devel. & Medical AffairsN/AN/A1966
Mr. David M. SchubertSr. VP of Regulatory & QualityN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Corporate governance

Chiasma, Inc.’s ISS governance QualityScore as of 1 July 2021 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.